PERSISTENCE ON GOLIMUMAB AS SECOND LINE BIOLOGICAL THERAPY IN PATIENTS WITH SPONDYLOARTHRITIS (AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS). GO-BEYOND, A RETROSPECTIVE STUDY

Gonzalez Fernandez, C. M.Alegre-Sancho, J. J.Garcia-Carazo, S.Rodriguez-Heredia, J. M.Bachiller-Corral, J.Martin Lopez, M.Retuerto Guerrero, M.Martin Santos, J. M.Alvarez-Rivas, N.Egues Dubuc, C. A.Villa-Blanco, I.Laiz, A.Tovar Beltran, J. V.Beltran, E.Raya, E.Ibanez Bosch, R.Manero, J.Pons Dolset, J.Garcia Magallon, B.Arteaga, M. J.Cea-Calvo, L.Juanola Roura, X.2025-01-072025-01-072018-06-010003-4967https://hdl.handle.net/10668/26047enPERSISTENCE ON GOLIMUMAB AS SECOND LINE BIOLOGICAL THERAPY IN PATIENTS WITH SPONDYLOARTHRITIS (AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS). GO-BEYOND, A RETROSPECTIVE STUDYconference outputopen access10.1136/annrheumdis-2018-eular.21641468-2060https://ard.bmj.com/content/annrheumdis/77/Suppl_2/1543.1.full.pdf444351004411